FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.4.11  |  FHIR Version n/a  User: [n/a]

Resource CodeSystem/FHIR Server from package hl7.terminology#current (46 ms)

Package hl7.terminology
Type CodeSystem
Id Id
FHIR Version R5
Source http://terminology.hl7.org/https://build.fhir.org/ig/HL7/UTG/CodeSystem-v3-nciThesaurus.html
Url http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
Version 3.0.0
Status active
Date 2022-10-13T00:00:00-04:00
Name NciThesaurus
Title NCI Thesaurus
Experimental False
Realm uv
Authority hl7
Description NCI Thesaurus NCI Thesaurus is a biomedical thesaurus created specifically to meet the needs of the cancer research community, especially those engaged in translational research NCI Thesaurus is produced by the NCI Enterprise Vocabulary Services project. The NCI Thesaurus is provided under an open content license.
Content not-present

Resources that use this resource

CodeSystem
http://hl7.org/fhir/us/pq-cmc-fda/CodeSystem/cmc-hierarchy-supplement PQ-CMC-FDA NCIt Hieararchy Supplement
http://hl7.org/fhir/us/icsr-ae-reporting/ValueSet/PatientMilitaryStatus Patient Military Status
http://hl7.org/fhir/us/mcode/ValueSet/mcode-all-risk-assessment-value-vs Acute Lymphoblastic Leukemia (ALL) Risk Assessment Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-binet-stage-value-vs Binet Stage Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-cancer-stage-type-vs Cancer Stage Type Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-cancer-stage-value-vs Cancer Stage Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-cancer-staging-method-vs Cancer Staging Method Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-deauville-scale-vs Deauville Scale Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-figo-stage-value-vs FIGO Stage Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-international-retinoblastoma-stage-value-vs International Retinoblastoma Stage Value
http://hl7.org/fhir/us/mcode/ValueSet/mcode-lansky-play-performance-vs Lansky Play Performance Status VS
http://hl7.org/fhir/us/mcode/ValueSet/mcode-lymphoma-stage-value-vs Lymphoma Stage Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-lymphoma-staging-method-vs Lymphoma Staging System Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-myeloma-iss-stage-value-vs International Staging System (ISS) for Myeloma Stage Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-myeloma-riss-stage-value-vs Revised International Staging System (ISS) for Multiple Myeloma Stage Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-neuroblastoma-INRGSS-value-vs International Neuroblastoma Risk Group Staging System (INRGSS) for Neuroblastoma Risk Assessment Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-pretext-stage-value-vs PRETEXT Stage Value
http://hl7.org/fhir/us/mcode/ValueSet/mcode-rai-stage-value-vs Rai Stage Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-rai-staging-method-vs Rai Staging System Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-rhabdomyosarcoma-assessment-value-vs Rhabdomyosarcoma Assessment Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-rhabdomyosarcoma-clinical-group-value-vs Rhabdomyosarcoma Clinical Group Value
http://hl7.org/fhir/us/mcode/ValueSet/mcode-risk-assessment-type-vs Risk Assessment Type Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-risk-assessment-vs Risk Assessment Value Set
http://hl7.org/fhir/us/mcode/ValueSet/mcode-tnm-staging-method-vs TNM Staging Method Value Set
http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-causality-relatedness Adverse Event Clinical Research Causality Relatedness
http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-grades Adverse Event Clinical Research Grades
http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-outcomes Adverse Event Clinical Research Outcomes
http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-seriousness-criteria Adverse Event Clinical Research Seriousness Criteria
http://hl7.org/fhir/uv/emedicinal-product-info/ValueSet/propertyColor Color of the product
http://hl7.org/fhir/uv/emedicinal-product-info/ValueSet/propertyFlavor Flavor of the product
http://hl7.org/fhir/uv/emedicinal-product-info/ValueSet/propertyShape Shape of the product
http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/DiagnosticMarker Diagnostic Marker
http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/HistologicalDiagnosis HistologicalDiagnosis
http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/TumorGrade Tumor Grade
http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/TumorProgression Tumor Progression
http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/TumorStage Tumor Stage
http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/phenotypic-abnormality Phenotypic abnormality ValueSet
http://hl7.org/fhir/us/codex-radiation-therapy/ValueSet/codexrt-radiotherapy-adverse-event-termVS Adverse Event Terms Value Set
http://hl7.org/fhir/us/spl/ValueSet/valueset-businessOperationQualifiers Business Operation Qualifiers
http://hl7.org/fhir/us/spl/ValueSet/valueset-establishmentBusinessOperations Establishment Business Operations
http://hl7.org/fhir/us/spl/ValueSet/valueset-gdufaFacilityBusinessOperationQualifiers GDUFA Facility Business Operation Qualifiers
http://hl7.org/fhir/us/spl/ValueSet/valueset-gdufaFacilityBusinessOperations GDUFA Facility Business Operations
http://hl7.org/fhir/us/spl/ValueSet/valueset-labelerBusinessOperations Labeler Business Operations
http://hl7.org/fhir/us/spl/ValueSet/valueset-splColor SPL Color
http://hl7.org/fhir/us/spl/ValueSet/valueset-splComboProductType SPL Combo Product Type
http://hl7.org/fhir/us/spl/ValueSet/valueset-splDoseForm SPL Dose Form
http://hl7.org/fhir/us/spl/ValueSet/valueset-splFlavor SPL Flavor
http://hl7.org/fhir/us/spl/ValueSet/valueset-splMarketingCategories SPL Marketing Categories
http://hl7.org/fhir/us/spl/ValueSet/valueset-splOperationType SPL Operation Type
http://hl7.org/fhir/us/spl/ValueSet/valueset-splPackageTypes SPL Package Types
http://hl7.org/fhir/us/spl/ValueSet/valueset-splRouteOfAdministration SPL Route of Administration
http://hl7.org/fhir/us/spl/ValueSet/valueset-splShape SPL Shape
http://hl7.org/fhir/us/spl/ValueSet/valueset-splSpecialMeasures SPL Special Measures
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/capsule-classification-category Capsule Shell Classification Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/cmc-product-name-types-vs Product Name Types Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-batch-utilization-terminology Batch utilization Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-chemical-structure-datafile-type-terminology Chemical Structure Data File Type Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-closure-type-terminology Closure Type Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-coating-purpose Coating Purpose Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-container-type-terminology Container Type Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-drug-product-component-function-category-terminology Drug Product Component Function Category Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-excipient-function-terminology Excipient Function Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-impurity-classification-terminology Impurity Classification Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-manufactured-dose-form-terminology Manufactured Dose Form Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-org-identifier-type-terminology Organization-Site Identifier Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-product-part-ingredient-physical-location Ingredient Location Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-product-part-type Product Part Type Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-quality-benchmark-terminology Quality Benchmark Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-release-mechanism Release Mechanism Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-release-profile Release Profile Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-representation-types Representation Types
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-source-type-terminology Source Type Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-specification-status-terminology Specification Status Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-specification-type-terminology Specification Type Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-strength-type-terminology Strength Type Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-substance-name-type Substance Name Type
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-test-category-terminology Test Category Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-test-method-origin-terminology Test Method Origin Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-test-usage-terminology Test Usage Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/spl-drug-route-of-administration-terminology Drug Route Of Administration Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/spl-pharmaceutical-dosage-form-terminology Pharmaceutical Dosage Form Terminology
http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/substance-classification Substance Classification
http://hl7.org/fhir/uv/genomics-reporting/ValueSet/molecular-biomarker-code-vs Molecular Biomarker Codes
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-cd-datacollected-nci NFDI4Health Data Collected [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-cd-information-sources-nci-local NFDI4Health Data Collected [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-id-type-nci-local NFDI4Health VS MDS ID Type [NCI, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-identifier-type-related-artifact-nci-local NFDI4Health VS MDS Identifier Type Related Artifact [NCI, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-mortality-data-nci NFDI4Health VS MDS Mortality Data [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-ne-instrument-nci-local NFDI4Health NE Instrument [NCI, Local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-ne-mode-nci-msh-local NFDI4Health NE Mode [NCI, MeSH, Local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-organisational-roles-nci-local NFDI4Health VS MDS Organisational Roles [NCI, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-personal-roles-nci-local NFDI4Health VS MDS Personal Roles [NCI, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-population-coverage-nci NFDI4Health VS MDS Population Coverage [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-resource-type-general-nci-msh-local NFDI4Health VS MDS Resource Type General [NCI, MSH, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-resource-type-nci-local NFDI4Health VS MDS Resource Type [NCI, Local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-allocation-nci NFDI4Health VS MDS Study Allocation [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-arm-group-type-nci NFDI4Health VS MDS Study Arm Group Type [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-assessments-sct-nci NFDI4Health VS MDS Study Assessments [SCT, NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-biospecimen-retention-nci NFDI4Health VS MDS Study Biospecimen Retention [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-conditions-classification-nci-local NFDI4Health VS MDS Study Conditions Classification [NCI, Local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-data-sharing-plan-ds-sct-nci NFDI4Health VS MDS Study Data Sharing Plan Datashield [SCT, NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-data-sharing-plan-sup-inf-nci-local NFDI4Health VS MDS Study Data Sharing Plan Supporting Information [NCI, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-data-sources-general-nci-local NFDI4Health VS MDS Study Data Sources General [NCI, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-data-sources-imaging-nci NFDI4Health VS MDS Study Data Sources Imaging [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-data-sources-omics-nci NFDI4Health VS MDS Study Data Sources Omics [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-ds-biosamples-sct-nci NFDI4Health VS MDS Study Data Sources Biosamples [SCT, NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-ethics-committee-approval-nci-local NFDI4Health VS MDS Study Ethics Commitee Approval [NCI, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-exposure-type-nci NFDI4Health VS MDS Study Exposure Type [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-group-characteristics-nci NFDI4Health VS MDS Study Group Characteristics [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-intervention-type-nci NFDI4Health VS MDS Study Intervention Type [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-masking-roles-nci-local NFDI4Health VS MDS Study Masking Roles [NCI, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-outcome-type-nci NFDI4Health VS MDS Study Outcome Type [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-overall-status-nci-local NFDI4Health VS MDS Study Overall Status [NCI, Local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-phase-nci NFDI4Health VS MDS Study Phase [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-primary-design-nci NFDI4Health VS MDS Study Primary Design [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-primary-purpose-hl7-nci NFDI4Health VS MDS Study Primary Purpose [HL7, NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-recruitment-register-nci-sct-local NFDI4Health VS MDS Study Recruitment Register [NCI, SCT, Local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-sampling-method-nci-local NFDI4Health VS MDS Study Sampling Method [NCI, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-sampling-method-non-prob-nci-local NFDI4Health VS MDS Study Sampling Method Non Probability [NCI, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-sampling-prob-method-nci-local NFDI4Health VS MDS Study Sampling Probability Method [NCI, Local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-time-perspectives-nci NFDI4Health VS MDS Study Time Perspectives [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-type-interventional-nci NFDI4Health VS MDS Study Type Interventional [NCI]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-type-non-interventional-nci-msh-local NFDI4Health VS MDS Study Type Non Interventional [NCI, MSH, local]
https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-yes-no-undecided-snomedct-nci NFDI4Health VS MDS Yes, No, Undecided [SNOMED CT, NCI]
http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-causality-relatedness Adverse Event Clinical Research Causality Relatedness
http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-grades Adverse Event Clinical Research Grades
http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-outcomes Adverse Event Clinical Research Outcomes
http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-seriousness-criteria Adverse Event Clinical Research Seriousness Criteria
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.30 AdministrationUnitDoseForm
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.46 Device Magnetic resonance (MR) Safety
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.47 Device Latex Safety
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.48 Implantable Device Status
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.292 Non pharmacologic treatments for chronic pain NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.36 Non pharmacologic treatments for chronic pain
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.100 MMR Proficient
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.11 Estrogen Receptor Test for Orserdu
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.116 Localized Bladder Cancer Staging
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.119 Localized Bladder Cancer T Stage
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.128 FGFR3 Gene
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.13 HER2 Negative
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.131 FGFR3 Gene Interpretation Positive NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.133 FGFR3 Gene Interpretation Positive
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.135 FGFR3 Gene Interpretation Negative NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.137 FGFR3 Gene Interpretation Negative
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.138 FGFR3 Molecular Variants
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.190 Localized NSCLC Stage Group NCIM
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.192 Localized NSCLC Stage Group
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.198 EGFR Gene
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.203 EGFR Generic Molecular Variant NCIM
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.206 EGFR Molecular Variants Osimertinib PM
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.214 Radiation Treatment Delivery NCIM
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.216 Radiation Treatment Delivery
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.227 MET Exon 14 skipping molecular variant
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.235 ROS1 Repotrectinib Molecular Variants
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.237 ROS1 Negative (geneinterpretation) NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.238 ROS1 Negative (geneinterpretation) SNOMEDCT,NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.240 ROS1 results (HGNC)
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.246 RET Negative (geneinterpretaion) NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.247 RET Negative (geneinterpretaion) SNOMEDCT,NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.248 RET Fusion Molecular Variants
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.25 ESR1 Gene Test
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.26 ESR1 Genetic Mutation
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.260 ALK Positive (geneinterpretation) NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.261 ALK Positive (geneinterpretation) SNOMEDCT NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.263 ALK Negative (geneinterpretation) NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.264 ALK Negative (geneinterpretation) SNOMEDCT NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.277 Extensive SCLC Stage Group NCIM
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.278 Extensive SCLC Stage Group
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.28 Her2 Negative
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.30 HER2 Positive
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.305 HER2 Negative (geneinterpretation/Labtestvalue) NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.307 HER2 Negative (geneinterpretation/Labtestvalue)
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.311 Localized_Solid_Cancer_Stage Group NCIM
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.313 Localized_Solid_Cancer_Stage Group
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.314 Locally_Advanced_Solid_Cancer_Stage Group NCIM
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.315 Locally_Advanced_Solid_Cancer_Stage Group
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.316 Metastatic_Solid_Cancer_Stage Group NCIM
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.317 Metastatic_Solid_Cancer_Stage Group
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.319 Solid Cancer T Stage NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.32 HER2 Positive
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.320 Solid Cancer T Stage codes
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.325 RET fusion Molecular Variants_Solid_Cancer
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.344 PTEN_gene
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.346 PIK3CA_gene
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.348 AKTI_gene
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.350 Progesterone_receptor_gene
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.352 Estrogen_receptor_gene
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.359 HER2_IHC_test_Gene
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.372 HER2 test_gene
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.416 KRAS_G12C_MV
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.429 Localized_Endometerial_Stage Group NCIM
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.460 Localized_Endometerial_Stage Group_SNOMED/NCIM
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.465 NTRK Repotrectinib Molecular Variants
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.55 MSI High
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.57 Early Stage IIB or lower
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.60 MMR Deficient
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.61 Stage IIB or lower and limited
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.63 Stage III or higher
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.64 Stage III or higher
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.66 Staging Unknown
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.67 Staging Unknown
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.84 RAS Gene Interpretation Negative NCM
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.85 RAS Gene Negative
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.9 ER Test for Orserdu
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.91 MSI High NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.94 MSI Low NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.95 MSI Low
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.96 MMR Deficient NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.99 MMR Proficient NCI
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.22 Route of Administration of Therapeutic Agents
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.11 Medication Product Form
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.7 SPL Drug Route of Administration Terminology
http://uk-koeln.de/fhir/ValueSet/nNGM/anforderung-liquidBiopsy ValueSet - nNGM - Anforderung Liquid Biopsy
http://uk-koeln.de/fhir/ValueSet/nNGM/anforderung-molekularpathologie ValueSet - nNGM - Anforderung Molekularpathologie
http://uk-koeln.de/fhir/ValueSet/nNGM/MaterialTyp ValueSet - nNGM - MaterialTyp
http://uk-koeln.de/fhir/ValueSet/nNGM/tki-resistenz ValueSet - nNGM - TKI Resistenz

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: CodeSystem v3-nciThesaurus

This case-sensitive code system http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl defines codes, but no codes are represented here

Source

{
  "resourceType" : "CodeSystem",
  "id" : "v3-nciThesaurus",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem v3-nciThesaurus</b></p><a name=\"v3-nciThesaurus\"> </a><a name=\"hcv3-nciThesaurus\"> </a><a name=\"v3-nciThesaurus-en-US\"> </a><p>This case-sensitive code system <code>http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl</code> defines codes, but no codes are represented here</p></div>"
  },
  "url" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.26.1.1"
    }
  ],
  "version" : "3.0.0",
  "name" : "NciThesaurus",
  "title" : "NCI Thesaurus",
  "status" : "active",
  "experimental" : false,
  "date" : "2022-10-13T00:00:00-04:00",
  "publisher" : "TBD - External Body",
  "contact" : [
    {
      "name" : "National Cancer Institute"
    }
  ],
  "description" : "NCI Thesaurus NCI Thesaurus is a biomedical thesaurus created specifically to meet the needs of the cancer research community, especially those engaged in translational research NCI Thesaurus is produced by the NCI Enterprise Vocabulary Services project. The NCI Thesaurus is provided under an open content license.",
  "caseSensitive" : true,
  "content" : "not-present"
}

XIG built as of ??metadata-date??. Found ??metadata-resources?? resources in ??metadata-packages?? packages.